The ESC guidelines [24] recommend the use of four main groups of drugs in heart failure therapy: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or angiotensin receptor/neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2is for HFrEF. The gene discussed is ACE; the disease is heart failure.